There was no significant difference between BCS and PVT for the prevalence of the JAK2 V617F mutation (p = 0.989), except that a significantly higher female predominance (p < 0.001), younger age of thrombosis diagnosis (p = 0.007) [69], and higher platelet counts (p = 0.004) were observed in BCS with JAK2 V617F. Here, JAK2 is linked to deep vein thrombosis.